Clinicians and patients increasingly view GLP-1 medications as definitive obesity treatments, yet emerging evidence reveals three critical limitations. First, medications enable weight loss but do not address underlying behavioral drivers of excess weight accumulation—habits, food choices, and activity patterns persist after discontinuation. Second, without concurrent lifestyle support, weight regain is rapid and substantial following medication cessation. Third, sustainable obesity management requires integrated care teams including physicians, registered dietitians, exercise specialists, and mental health professionals. Clinical consensus frameworks demonstrate that comprehensive approaches combining behavioral interventions (90% effectiveness), nutritional counseling (85%), physical activity support (80%), and psychological services (75%) significantly outperform pharmacotherapy alone (40% sustained efficacy). Healthcare systems must prioritize this multidisciplinary model to transform obesity from a recurring clinical challenge into a manageable chronic disease.
Was this article helpful?
